The webinar will feature presentations by Mitchell Kronenberg, Ph.D. (La Jolla Institute For Immunology) and Anastasios Karadimitris (MBBS), Ph.D. MRCP FRCPath (Imperial College London).

Dr. Kroenberg will provide an overview on invariant natural killer T cell (iNKT) cells and their mechanism of action to enable multiple parts of the immune system to attack and kill cancer. Dr. Karadimitris will discuss the current iNKT clinical data landscape.

Portage Biotech’s Chief Executive Officer and Director Ian B. Walters, M.D., MBA, will then discuss their novel clinical development strategy and timing using iNKT agonists to convert PDL1 negative tumors to PDL1 positive, overcoming PD-1 antibody resistance, enabling checkpoint inhibitors to be used in immunologically cold tumors.

A live Q&A session will follow the formal presentations.